Global Live Biotherapeutic Products (LBP) CDMO Service Market Research Report 2024

Publication ID:

PB511246634

Publication Date:

November 18, 2024

Pages:

Publisher:

MRRPB5

Countries:

Global [1]

USD 2,900.00

IT Services [2]

Computing & Electronics [3]

Description:

The global Live Biotherapeutic Products (LBP) CDMO Service market was valued at US$ 109 million in 2023 and is anticipated to reach US$ 425 million by 2030, witnessing a CAGR of 21.5% during the forecast period 2024-2030.
Live Biotherapeutic Products (LBPs) are biotherapeutic products based on live microorganisms that are intended to treat or prevent disease by modulating the microbiome. These products are usually prepared from specific strains of microorganisms that have potential therapeutic effects, such as improving gut health, boosting the immune system, or reducing inflammation.CDMOs specializing in these fields have the expertise and infrastructure to support developing and manufacturing these complex therapies, which require specialized equipment and facilities. As a result, pharmaceutical and biotech companies can outsource their production to CDMOs, allowing them to focus on research and development.
North American market for Live Biotherapeutic Products (LBP) CDMO Service is estimated to increase from $ million in 2023 to reach $ million by 2030, at a CAGR of % during the forecast period of 2024 through 2030.
Asia-Pacific market for Live Biotherapeutic Products (LBP) CDMO Service is estimated to increase from $ million in 2023 to reach $ million by 2030, at a CAGR of % during the forecast period of 2024 through 2030.
The global market for Live Biotherapeutic Products (LBP) CDMO Service in Digestive System Diseases is estimated to increase from $ million in 2023 to $ million by 2030, at a CAGR of % during the forecast period of 2024 through 2030.
The major global companies of Live Biotherapeutic Products (LBP) CDMO Service include Lallemand Health Solutions, Wacker Chemie AG, Biose Industrie, List Biological Labs, Inc., NIZO, SGS (Quay Pharmaceuticals), Assembly Biosciences, Inc., Recipharm (Arranta Bio), Bacthera (Novonesis+Lonza), Smaltis, etc. In 2023, the world's top three vendors accounted for approximately % of the revenue.
This report aims to provide a comprehensive presentation of the global market for Live Biotherapeutic Products (LBP) CDMO Service, with both quantitative and qualitative analysis, to help readers develop business/growth strategies, assess the market competitive situation, analyze their position in the current marketplace, and make informed business decisions regarding Live Biotherapeutic Products (LBP) CDMO Service.
The Live Biotherapeutic Products (LBP) CDMO Service market size, estimations, and forecasts are provided in terms of and revenue ($ millions), considering 2023 as the base year, with history and forecast data for the period from 2019 to 2030. This report segments the global Live Biotherapeutic Products (LBP) CDMO Service market comprehensively. Regional market sizes, concerning products by Type, by Application, and by players, are also provided.
For a more in-depth understanding of the market, the report provides profiles of the competitive landscape, key competitors, and their respective market ranks. The report also discusses technological trends and new product developments.
The report will help the Live Biotherapeutic Products (LBP) CDMO Service companies, new entrants, and industry chain related companies in this market with information on the revenues for the overall market and the sub-segments across the different segments, by company, by Type, by Application, and by regions.
Market Segmentation
By Company
Lallemand Health Solutions
Wacker Chemie AG
Biose Industrie
List Biological Labs, Inc.
NIZO
SGS (Quay Pharmaceuticals)
Assembly Biosciences, Inc.
Recipharm (Arranta Bio)
Bacthera (Novonesis+Lonza)
Smaltis
Lonza
vermicon AG
Cerbios-Pharma SA
Segment by Type
Solid Dosage Form
Liquid Dosage Form
Segment by Application
Digestive System Diseases
Immune System Diseases
Metabolic Diseases
Other
By Region
North America
United States
Canada
Asia-Pacific
China
Japan
South Korea
Southeast Asia
India
Australia
Rest of Asia
Europe
Germany
France
U.K.
Italy
Russia
Nordic Countries
Rest of Europe
Latin America
Mexico
Brazil
Rest of Latin America
Middle East & Africa
Turkey
Saudi Arabia
UAE
Rest of MEA
Chapter Outline
Chapter 1: Introduces the report scope of the report, executive summary of different market segments (by Type, by Application, etc), including the market size of each market segment, future development potential, and so on. It offers a high-level view of the current state of the market and its likely evolution in the short to mid-term, and long term.
Chapter 2: Introduces executive summary of global market size, regional market size, this section also introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by companies in the industry, and the analysis of relevant policies in the industry.
Chapter 3: Detailed analysis of Live Biotherapeutic Products (LBP) CDMO Service company competitive landscape, revenue market share, latest development plan, merger, and acquisition information, etc.
Chapter 4: Provides the analysis of various market segments by Type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter 5: Provides the analysis of various market segments by Application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter 6, 7, 8, 9, 10: North America, Europe, Asia Pacific, Latin America, Middle East and Africa segment by country. It provides a quantitative analysis of the market size and development potential of each region and its main countries and introduces the market development, future development prospects, market space, and capacity of each country in the world.
Chapter 11: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product sales, revenue, price, gross margin, product introduction, recent development, etc.
Chapter 12: The main points and conclusions of the report.

Please Note - This is an on demand report and will be delivered in 2 business days (48 hours) post payment.

Table Of Contents:

1 Report Overview
1.1 Study Scope
1.2 Market Analysis by Type
1.2.1 Global Live Biotherapeutic Products (LBP) CDMO Service Market Size Growth Rate by Type: 2019 VS 2023 VS 2030
1.2.2 Solid Dosage Form
1.2.3 Liquid Dosage Form
1.3 Market by Application
1.3.1 Global Live Biotherapeutic Products (LBP) CDMO Service Market Growth by Application: 2019 VS 2023 VS 2030
1.3.2 Digestive System Diseases
1.3.3 Immune System Diseases
1.3.4 Metabolic Diseases
1.3.5 Other
1.4 Assumptions and Limitations
1.5 Study Objectives
1.6 Years Considered
2 Global Growth Trends
2.1 Global Live Biotherapeutic Products (LBP) CDMO Service Market Perspective (2019-2030)
2.2 Global Live Biotherapeutic Products (LBP) CDMO Service Growth Trends by Region
2.2.1 Global Live Biotherapeutic Products (LBP) CDMO Service Market Size by Region: 2019 VS 2023 VS 2030
2.2.2 Live Biotherapeutic Products (LBP) CDMO Service Historic Market Size by Region (2019-2024)
2.2.3 Live Biotherapeutic Products (LBP) CDMO Service Forecasted Market Size by Region (2025-2030)
2.3 Live Biotherapeutic Products (LBP) CDMO Service Market Dynamics
2.3.1 Live Biotherapeutic Products (LBP) CDMO Service Industry Trends
2.3.2 Live Biotherapeutic Products (LBP) CDMO Service Market Drivers
2.3.3 Live Biotherapeutic Products (LBP) CDMO Service Market Challenges
2.3.4 Live Biotherapeutic Products (LBP) CDMO Service Market Restraints
3 Competition Landscape by Key Players
3.1 Global Top Live Biotherapeutic Products (LBP) CDMO Service Players by Revenue
3.1.1 Global Top Live Biotherapeutic Products (LBP) CDMO Service Players by Revenue (2019-2024)
3.1.2 Global Live Biotherapeutic Products (LBP) CDMO Service Revenue Market Share by Players (2019-2024)
3.2 Global Live Biotherapeutic Products (LBP) CDMO Service Market Share by Company Type (Tier 1, Tier 2, and Tier 3)
3.3 Global Key Players Ranking by Live Biotherapeutic Products (LBP) CDMO Service Revenue
3.4 Global Live Biotherapeutic Products (LBP) CDMO Service Market Concentration Ratio
3.4.1 Global Live Biotherapeutic Products (LBP) CDMO Service Market Concentration Ratio (CR5 and HHI)
3.4.2 Global Top 10 and Top 5 Companies by Live Biotherapeutic Products (LBP) CDMO Service Revenue in 2023
3.5 Global Key Players of Live Biotherapeutic Products (LBP) CDMO Service Head office and Area Served
3.6 Global Key Players of Live Biotherapeutic Products (LBP) CDMO Service, Product and Application
3.7 Global Key Players of Live Biotherapeutic Products (LBP) CDMO Service, Date of Enter into This Industry
3.8 Mergers & Acquisitions, Expansion Plans
4 Live Biotherapeutic Products (LBP) CDMO Service Breakdown Data by Type
4.1 Global Live Biotherapeutic Products (LBP) CDMO Service Historic Market Size by Type (2019-2024)
4.2 Global Live Biotherapeutic Products (LBP) CDMO Service Forecasted Market Size by Type (2025-2030)
5 Live Biotherapeutic Products (LBP) CDMO Service Breakdown Data by Application
5.1 Global Live Biotherapeutic Products (LBP) CDMO Service Historic Market Size by Application (2019-2024)
5.2 Global Live Biotherapeutic Products (LBP) CDMO Service Forecasted Market Size by Application (2025-2030)
6 North America
6.1 North America Live Biotherapeutic Products (LBP) CDMO Service Market Size (2019-2030)
6.2 North America Live Biotherapeutic Products (LBP) CDMO Service Market Growth Rate by Country: 2019 VS 2023 VS 2030
6.3 North America Live Biotherapeutic Products (LBP) CDMO Service Market Size by Country (2019-2024)
6.4 North America Live Biotherapeutic Products (LBP) CDMO Service Market Size by Country (2025-2030)
6.5 United States
6.6 Canada
7 Europe
7.1 Europe Live Biotherapeutic Products (LBP) CDMO Service Market Size (2019-2030)
7.2 Europe Live Biotherapeutic Products (LBP) CDMO Service Market Growth Rate by Country: 2019 VS 2023 VS 2030
7.3 Europe Live Biotherapeutic Products (LBP) CDMO Service Market Size by Country (2019-2024)
7.4 Europe Live Biotherapeutic Products (LBP) CDMO Service Market Size by Country (2025-2030)
7.5 Germany
7.6 France
7.7 U.K.
7.8 Italy
7.9 Russia
7.10 Nordic Countries
8 Asia-Pacific
8.1 Asia-Pacific Live Biotherapeutic Products (LBP) CDMO Service Market Size (2019-2030)
8.2 Asia-Pacific Live Biotherapeutic Products (LBP) CDMO Service Market Growth Rate by Country: 2019 VS 2023 VS 2030
8.3 Asia-Pacific Live Biotherapeutic Products (LBP) CDMO Service Market Size by Region (2019-2024)
8.4 Asia-Pacific Live Biotherapeutic Products (LBP) CDMO Service Market Size by Region (2025-2030)
8.5 China
8.6 Japan
8.7 South Korea
8.8 Southeast Asia
8.9 India
8.10 Australia
9 Latin America
9.1 Latin America Live Biotherapeutic Products (LBP) CDMO Service Market Size (2019-2030)
9.2 Latin America Live Biotherapeutic Products (LBP) CDMO Service Market Growth Rate by Country: 2019 VS 2023 VS 2030
9.3 Latin America Live Biotherapeutic Products (LBP) CDMO Service Market Size by Country (2019-2024)
9.4 Latin America Live Biotherapeutic Products (LBP) CDMO Service Market Size by Country (2025-2030)
9.5 Mexico
9.6 Brazil
10 Middle East & Africa
10.1 Middle East & Africa Live Biotherapeutic Products (LBP) CDMO Service Market Size (2019-2030)
10.2 Middle East & Africa Live Biotherapeutic Products (LBP) CDMO Service Market Growth Rate by Country: 2019 VS 2023 VS 2030
10.3 Middle East & Africa Live Biotherapeutic Products (LBP) CDMO Service Market Size by Country (2019-2024)
10.4 Middle East & Africa Live Biotherapeutic Products (LBP) CDMO Service Market Size by Country (2025-2030)
10.5 Turkey
10.6 Saudi Arabia
10.7 UAE
11 Key Players Profiles
11.1 Lallemand Health Solutions
11.1.1 Lallemand Health Solutions Company Details
11.1.2 Lallemand Health Solutions Business Overview
11.1.3 Lallemand Health Solutions Live Biotherapeutic Products (LBP) CDMO Service Introduction
11.1.4 Lallemand Health Solutions Revenue in Live Biotherapeutic Products (LBP) CDMO Service Business (2019-2024)
11.1.5 Lallemand Health Solutions Recent Development
11.2 Wacker Chemie AG
11.2.1 Wacker Chemie AG Company Details
11.2.2 Wacker Chemie AG Business Overview
11.2.3 Wacker Chemie AG Live Biotherapeutic Products (LBP) CDMO Service Introduction
11.2.4 Wacker Chemie AG Revenue in Live Biotherapeutic Products (LBP) CDMO Service Business (2019-2024)
11.2.5 Wacker Chemie AG Recent Development
11.3 Biose Industrie
11.3.1 Biose Industrie Company Details
11.3.2 Biose Industrie Business Overview
11.3.3 Biose Industrie Live Biotherapeutic Products (LBP) CDMO Service Introduction
11.3.4 Biose Industrie Revenue in Live Biotherapeutic Products (LBP) CDMO Service Business (2019-2024)
11.3.5 Biose Industrie Recent Development
11.4 List Biological Labs, Inc.
11.4.1 List Biological Labs, Inc. Company Details
11.4.2 List Biological Labs, Inc. Business Overview
11.4.3 List Biological Labs, Inc. Live Biotherapeutic Products (LBP) CDMO Service Introduction
11.4.4 List Biological Labs, Inc. Revenue in Live Biotherapeutic Products (LBP) CDMO Service Business (2019-2024)
11.4.5 List Biological Labs, Inc. Recent Development
11.5 NIZO
11.5.1 NIZO Company Details
11.5.2 NIZO Business Overview
11.5.3 NIZO Live Biotherapeutic Products (LBP) CDMO Service Introduction
11.5.4 NIZO Revenue in Live Biotherapeutic Products (LBP) CDMO Service Business (2019-2024)
11.5.5 NIZO Recent Development
11.6 SGS (Quay Pharmaceuticals)
11.6.1 SGS (Quay Pharmaceuticals) Company Details
11.6.2 SGS (Quay Pharmaceuticals) Business Overview
11.6.3 SGS (Quay Pharmaceuticals) Live Biotherapeutic Products (LBP) CDMO Service Introduction
11.6.4 SGS (Quay Pharmaceuticals) Revenue in Live Biotherapeutic Products (LBP) CDMO Service Business (2019-2024)
11.6.5 SGS (Quay Pharmaceuticals) Recent Development
11.7 Assembly Biosciences, Inc.
11.7.1 Assembly Biosciences, Inc. Company Details
11.7.2 Assembly Biosciences, Inc. Business Overview
11.7.3 Assembly Biosciences, Inc. Live Biotherapeutic Products (LBP) CDMO Service Introduction
11.7.4 Assembly Biosciences, Inc. Revenue in Live Biotherapeutic Products (LBP) CDMO Service Business (2019-2024)
11.7.5 Assembly Biosciences, Inc. Recent Development
11.8 Recipharm (Arranta Bio)
11.8.1 Recipharm (Arranta Bio) Company Details
11.8.2 Recipharm (Arranta Bio) Business Overview
11.8.3 Recipharm (Arranta Bio) Live Biotherapeutic Products (LBP) CDMO Service Introduction
11.8.4 Recipharm (Arranta Bio) Revenue in Live Biotherapeutic Products (LBP) CDMO Service Business (2019-2024)
11.8.5 Recipharm (Arranta Bio) Recent Development
11.9 Bacthera (Novonesis+Lonza)
11.9.1 Bacthera (Novonesis+Lonza) Company Details
11.9.2 Bacthera (Novonesis+Lonza) Business Overview
11.9.3 Bacthera (Novonesis+Lonza) Live Biotherapeutic Products (LBP) CDMO Service Introduction
11.9.4 Bacthera (Novonesis+Lonza) Revenue in Live Biotherapeutic Products (LBP) CDMO Service Business (2019-2024)
11.9.5 Bacthera (Novonesis+Lonza) Recent Development
11.10 Smaltis
11.10.1 Smaltis Company Details
11.10.2 Smaltis Business Overview
11.10.3 Smaltis Live Biotherapeutic Products (LBP) CDMO Service Introduction
11.10.4 Smaltis Revenue in Live Biotherapeutic Products (LBP) CDMO Service Business (2019-2024)
11.10.5 Smaltis Recent Development
11.11 Lonza
11.11.1 Lonza Company Details
11.11.2 Lonza Business Overview
11.11.3 Lonza Live Biotherapeutic Products (LBP) CDMO Service Introduction
11.11.4 Lonza Revenue in Live Biotherapeutic Products (LBP) CDMO Service Business (2019-2024)
11.11.5 Lonza Recent Development
11.12 vermicon AG
11.12.1 vermicon AG Company Details
11.12.2 vermicon AG Business Overview
11.12.3 vermicon AG Live Biotherapeutic Products (LBP) CDMO Service Introduction
11.12.4 vermicon AG Revenue in Live Biotherapeutic Products (LBP) CDMO Service Business (2019-2024)
11.12.5 vermicon AG Recent Development
11.13 Cerbios-Pharma SA
11.13.1 Cerbios-Pharma SA Company Details
11.13.2 Cerbios-Pharma SA Business Overview
11.13.3 Cerbios-Pharma SA Live Biotherapeutic Products (LBP) CDMO Service Introduction
11.13.4 Cerbios-Pharma SA Revenue in Live Biotherapeutic Products (LBP) CDMO Service Business (2019-2024)
11.13.5 Cerbios-Pharma SA Recent Development
12 Analyst's Viewpoints/Conclusions
13 Appendix
13.1 Research Methodology
13.1.1 Methodology/Research Approach
13.1.1.1 Research Programs/Design
13.1.1.2 Market Size Estimation
13.1.1.3 Market Breakdown and Data Triangulation
13.1.2 Data Source
13.1.2.1 Secondary Sources
13.1.2.2 Primary Sources
13.2 Author Details
13.3 Disclaimer

Companies Mentioned:

Lallemand Health Solutions
Wacker Chemie AG
Biose Industrie
List Biological Labs, Inc.
NIZO
SGS (Quay Pharmaceuticals)
Assembly Biosciences, Inc.
Recipharm (Arranta Bio)
Bacthera (Novonesis+Lonza)
Smaltis
Lonza
vermicon AG
Cerbios-Pharma SA

License Types:

Single User License (PDF)

This license allows for use of a publication by one person.
This person may print out a single copy of the publication.
This person can include information given in the publication in presentations and internal reports by providing full copyright credit to the publisher.
This person cannot share the publication (or any information contained therein) with any other person or persons.
Unless a Enterprise License is purchased, a Single User License must be purchased for every person that wishes to use the publication within the same organization.
Customers who infringe these license terms are liable for a Global license fee.

听

Site License (PDF)*

This license allows for use of a publication by all users within one corporate location, e.g. a regional office.
These users may print out a single copy of the publication.
These users can include information given in the publication in presentations and internal reports by providing full copyright credit to the publisher.
These users cannot share the publication (or any information contained therein) with any other person or persons outside the corporate location for which the publication is purchased.
Unless a Enterprise License is purchased, a Site User License must be purchased for every corporate location by an organization that wishes to use the publication within the same organization.
Customers who infringe these license terms are liable for a Global license fee.

听

Global License (PDF)*

This license allows for use of a publication by unlimited users within the purchasing organization e.g. all employees of a single company.
Each of these people may use the publication on any computer, and may print out the report, but may not share the publication (or any information contained therein) with any other person or persons outside of the organization.
These employees of purchasing organization can include information given in the publication in presentations and internal reports by providing full copyright credit to the publisher.

*If Applicable.

91制片厂